Skip to main content
. 2022 Jun 23;127(6):1153–1161. doi: 10.1038/s41416-022-01892-6

Fig. 2. Left: progression-free survival (PFS) of VOR/HCQ versus RGF.

Fig. 2

Median PFS was 1.90 months (95% CI 1.87 to undefined) with VOR/HCQ versus 4.35 months (95% CI 2.63 to undefined) with RGF (P = 0.032, HR: 2.277, 95% CI: 1.058–4.898). Right: overall survival (OS) with VOR/HCQ versus RGF in mCRC. The median OS was 6.77 months (95% CI 4.0 to undefined) with VOR/HCQ versus 7.23 months [95% CI 4.8–10.8] with RGF (P = 0.90, HR: 1.05, 95% CI: 0.481–2.3). VOR   vorinostat, HCQ   hydroxychloroquine, RGF  regorafenib.